Biopharma company Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) on Monday reported a robust business update for Q4 2023, disclosing preliminary, unaudited financial data. The company reported strong Q4 product revenue growth, estimating net TARPEYO revenues at USD31-33m, marking substantial progress over Q3.

Preliminary figures for the full year 2023 indicate a noteworthy performance, with Net TARPEYO revenues reaching USD100-102mn, reflecting a remarkable 170% YoY growth compared to 2022. Total revenues for 2023 are anticipated to be USD110-113m, driven by milestone payments and royalty income from the Nefecon franchise outside the US.

Q4 saw a record quarter in terms of enrollments, with 555 new TARPEYO prescriptions. These estimates are preliminary and presented as ranges due to ongoing financial closing procedures, with final results potentially varying from these initial figures.

Calliditas is dedicated to identifying, developing, and commercialising novel treatments for orphan indications with significant unmet medical needs.